SCHEMBL856163

SCHEMBL856163

Nc1ncc(Br)cc1S(=O)(=O)NCC1CN(C(=O)O)C1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GFER P55789 2/20 0.52
HSD17B10 Q99714 4/20 0.51
ALDH1A1 P00352 2/20 0.51
GAA P10253 2/20 0.51
KDM4E B2RXH2 3/20 0.50
MAPT P10636 3/20 0.48
LMNA P02545 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
KMT2A Q03164 6/20 0.45
MEN1 O00255 5/20 0.45
RAB9A P51151 1/20 0.45
PIK3C3 Q8NEB9 1/20 0.44
PLA2G1B P04054 1/20 0.44
ATG4B Q9Y4P1 1/20 0.44
NPC1 O15118 1/20 0.44
NPY1R P25929 1/20 0.41
NPY2R P49146 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL859140 0.91 HSD17B10 (0.54) GFERHSD17B10ALDH1A1GAAKDM4E
SCHEMBL856213 0.90 HSD17B10 (0.50) GFERHSD17B10ALDH1A1GAAKDM4E
SCHEMBL859649 0.85 HSD17B10 (0.53) GFERHSD17B10ALDH1A1GAAKDM4E
SCHEMBL855802 0.80 HSD17B10 (0.56) GFERHSD17B10ALDH1A1GAAKDM4E
SCHEMBL858759 0.80 HSD17B10 (0.56) GFERHSD17B10ALDH1A1GAAKDM4E
SCHEMBL855801 0.80 HSD17B10 (0.56) GFERHSD17B10ALDH1A1GAAKDM4E
SCHEMBL3767884 0.80 HSD17B10 (0.50) GFERHSD17B10ALDH1A1GAAKDM4E
SCHEMBL859184 0.79 HSD17B10 (0.52) GFERHSD17B10ALDH1A1GAAKDM4E
SCHEMBL3758643 0.79 HSD17B10 (0.52) GFERHSD17B10ALDH1A1GAAKDM4E
SCHEMBL857222 0.79 HSD17B10 (0.52) GFERHSD17B10ALDH1A1GAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-04-17 US disclosed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
EP-2640366-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE Exelixis, Inc. (US) 2013-09-25 EP disclosed
WO-2012068096-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2012-05-24 WO disclosed
EP-2432779-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2012-03-28 EP disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA GFER 3964/4885HSD17B10 1254/4885ALDH1A1 3395/4885
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA GFER 4111/4885HSD17B10 711/4885ALDH1A1 3533/4885
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA GFER 4167/4885HSD17B10 1066/4885ALDH1A1 3049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.